Contact Us
Drug Search Results
More Filters [+]

AZD6482

Alternative Names: azd6482
Latest Update: 2024-03-02
Latest Update Note: PubMed Publication

Product Description

AZD6482 is a new drug substance aiming to prevent blood clots which may arise in atherosclerotic blood vessels and cause myocardial infarction or stroke. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00688714)

Mechanisms of Action: p110B PI3K Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD6482

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Stroke|Myocardial Infarction|Healthy Volunteers|Injuries/wounds Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
D1700C00001

P1

Completed

Stroke|Myocardial Infarction

2008-05-01

D1700C00004

P1

Completed

Healthy Volunteers|Injuries/wounds Unspecified

None

Recent News Events

Date

Type

Title

03/02/2024

PubMed

 Comprehensive analysis of T cell exhaustion related signature for predicting prognosis and immunotherapy response in HNSCC.

01/31/2024

PubMed

 Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma.

07/27/2023

PubMed

 A novel stratification framework based on anoikis-related genes for predicting the prognosis in patients with osteosarcoma.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions